Personalized treatment for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer that cannot be cured with surgery, ablation, or radiation.
- Your liver cancer has gotten worse after you've tried a combination of targeted therapy and immunotherapy.
- You must be at least 18 years old and your life expectancy should be more than 3 months.
- Your daily activities should be mostly normal (you can care for yourself and are often out of bed).
- Your blood counts, liver, and kidney function need to be within certain limits (your doctor can check this).
- Women of childbearing age must have a negative pregnancy test, and all participants must agree to use birth control for about 24 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized combination treatment for unresectable (cannot be removed with surgery) liver cancer. It uses a special test to guide which drugs you receive, aiming to improve how well the treatment works for your specific tumor type.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.